Get the Stockscreener App
4.12
2.60%
-0.11
Prime Medicine Inc stock is traded at $4.12, with a volume of 2.13M.
It is down -2.60% in the last 24 hours and up +18.56% over the past month.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
See More
Previous Close:
$4.23
Open:
$4.28
24h Volume:
2.13M
Relative Volume:
0.65
Market Cap:
$743.70M
Revenue:
-
Net Income/Loss:
$-217.44M
P/E Ratio:
-1.8986
EPS:
-2.17
Net Cash Flow:
$-205.20M
1W Performance:
-0.24%
1M Performance:
+18.56%
6M Performance:
+21.18%
1Y Performance:
+86.85%
1-Day Range:
$4.12
$4.365
1-Week Range:
$4.10
$4.7652
52-Week Range:
$1.11
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Name
Prime Medicine Inc
Sector
Industry
Phone
617-465-0013
Address
60 FIRST ST., CAMBRIDGE
Compare PRME vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
4.12 | 763.56M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Downgrade | Citigroup | Buy → Neutral |
| May-20-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-20-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| May-20-24 | Initiated | H.C. Wainwright | Buy |
| May-16-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-24 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-24 | Initiated | TD Cowen | Buy |
| Apr-03-24 | Initiated | Wedbush | Outperform |
| Jan-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Oct-09-23 | Initiated | BMO Capital Markets | Outperform |
| Jul-31-23 | Initiated | Guggenheim | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Nov-14-22 | Initiated | Goldman | Neutral |
| Nov-14-22 | Initiated | JP Morgan | Overweight |
| Nov-14-22 | Initiated | Jefferies | Buy |
| Nov-14-22 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prime Medicine Inc Stock (PRME) Latest News
Prime Medicine, Inc. $PRME Shares Acquired by ARK Investment Management LLC - MarketBeat
Prime Medicine, Inc. $PRME Stock Position Increased by Amova Asset Management Americas Inc. - MarketBeat
Citizens reiterates Prime Medicine stock rating on PM359 pathway By Investing.com - Investing.com Canada
Prime Medicine (NASDAQ:PRME) Upgraded by Lifesci Capital to "Strong-Buy" Rating - MarketBeat
Prime Medicine unveils full year 2025 financial results and business update as progress advances - Traders Union
Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates - Nasdaq
Prime Medicine Reports 2025 Results, Advances Gene Editing Pipeline - TipRanks
Prime Medicine 2025 Net Loss Narrows as Revenue Rises -- Shares Fall Pre-Bell - marketscreener.com
Earnings Flash (PRME) Prime Medicine Posts 2025 Total Revenue $4.6M, vs. FactSet Est of $5.7M - marketscreener.com
Prime Medicine : March 2026 Corporate Presentation - marketscreener.com
Prime Medicine 2025 net loss widens, hurt by higher R&D expenses - TradingView
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates - The Manila Times
Prime Medicine (Nasdaq: PRME) details 2025 results, cash runway and gene-editing milestones - Stock Titan
Prime Medicine posts $201M loss advancing gene-editing therapies - Stock Titan
PRME Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Prime Medicine, Inc. (PRME) Announces Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget
Investment Report: What is the target price for Prime Medicine Inc stockJuly 2025 Fed Impact & Low Risk High Reward Trade Ideas - baoquankhu1.vn
HighTower Advisors LLC Buys 312,401 Shares of Prime Medicine, Inc. $PRME - MarketBeat
Stock Traders Buy Large Volume of Call Options on Prime Medicine (NYSE:PRME) - MarketBeat
Prime Medicine to Participate in Upcoming Investor Conferences - Bitget
Prime Medicine (NYSE:PRME) Trading 10.3% HigherStill a Buy? - MarketBeat
PRME (Prime Medicine) PB Ratio : 3.72 (As of Feb. 23, 2026) - GuruFocus
Prime Medicine (NASDAQ:PRME) Trading Up 1.2%Here's What Happened - MarketBeat
Jacob Funds Bets on Prime Medicine (PRME), a Next-Generation Gene Therapy Company - Insider Monkey
Prime Medicine, Inc. $PRME Shares Acquired by Alphabet Inc. - MarketBeat
Aug Catalysts: Is Seacoast Banking Corporation of Florida impacted by rising rates2025 Market Outlook & Weekly Watchlist of Top Performers - baoquankhu1.vn
Should I average down on Prime Medicine Inc. stockWeekly Investment Recap & Reliable Price Breakout Alerts - mfd.ru
Aug Analyst Calls: Is Prime Medicine Inc stock a smart retirement pick2025 Biggest Moves & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Prime Medicine, Inc. (NYSE:PRME) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Earnings Miss: Will Prime Medicine Inc stock hit new highs in YEARJuly 2025 Spike Watch & AI Driven Price Forecasts - baoquankhu1.vn
Prime Medicine Advances Wilson Disease Pipeline With New Prescreening Study - TipRanks
Institutional Owners May Ignore Prime Medicine, Inc.'s (NASDAQ:PRME) Recent US$66m Market Cap Decline as Longer-term Profits Stay in the Green - 富途牛牛
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) see US$110m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
What is the target price for Prime Medicine Inc. stockJuly 2025 Weekly Recap & Verified Trade Idea Suggestions - mfd.ru
Aug Selloffs: Should I average down on Prime Medicine Inc stockJuly 2025 Drop Watch & Intraday High Probability Setup Alerts - baoquankhu1.vn
Favourable Signals For Prime Medicine: Numerous Insiders Acquired Stock - Yahoo Finance
Prime Medicine (NASDAQ:PRME) Shares Down 5.6%What's Next? - MarketBeat
Prime Medicine (NYSE:PRME) Trading Down 5.5%What's Next? - MarketBeat
JonesTrading Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
Prime Medicine (NASDAQ:PRME) Shares Up 10.5%Here's Why - MarketBeat
Prime Medicine (NYSE:PRME) Shares Up 12.4%Time to Buy? - MarketBeat
Should I trade or invest in Prime Medicine IncJuly 2025 Highlights & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Targets Report: Is NEOV in accumulation or distribution phaseGap Down & Weekly Breakout Stock Alerts - baoquankhu1.vn
How Prime Medicine Inc. stock reacts to bond yieldsEarnings Trend Report & Long-Term Safe Return Strategies - bollywoodhelpline.com
Sumitomo Mitsui Trust Group Inc. Boosts Stake in Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Down 7.9%Should You Sell? - MarketBeat
Prime Medicine (NYSE:PRME) Trading Down 5.7%What's Next? - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Prime Medicine (NASDAQ:PRME) Shares Up 8.4%Should You Buy? - MarketBeat
PRME: Prime Editing's modular platform drives rapid clinical progress and strategic partnerships for broad disease impact - TradingView
Prime Medicine updates corporate strategy for Prime Editing platform - TipRanks
Prime Medicine Inc Stock (PRME) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):